Australia markets closed

Addex Therapeutics Ltd (ADDXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.56000.0000 (0.00%)
At close: 9:55AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5600
Open1.5600
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.5600 - 1.5600
52-week range1.5600 - 1.6500
Volume5,000
Avg. volume78
Market cap50.58M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)-0.4590
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.00
  • GlobeNewswire

    Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    Geneva, Switzerland, September 8, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (September 13 - 15, 2021). In his presentation, which is scheduled for Monday, September 13, 2021 at 07:00 ET / 13:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Adde

  • GlobeNewswire

    Addex to Present at the Swiss Biotech Day

    Geneva, Switzerland, September 2, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present a corporate overview at the Swiss Biotech Day, held September 7, 2021 at the Congress Center Basel, Messeplatz 21, 4058 Basel, Switzerland. Mr. Dyer’s presentation is scheduled for 13:15 in room Montreal. If you would like to schedule a meeting with Mr. Dyer, please

  • GlobeNewswire

    Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update

    Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M)Pivotal dipraglurant PD-LID study initiatedJanssen Pharmaceuticals started Phase 2 study in epilepsy with ADX71149Dipraglurant blepharospasm study on track to start in Q3 2021Completed $11.5M fundraising in January 2021 Geneva, Switzerland, August 5, 2021 - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulatio